Evidence map›Paper›PMID 31768799›Full record

ReviewCurrent oncology reports2019

Upfront Therapies and Downstream Effects: Navigating Late Effects in Childhood Cancer Survivors in the Current Era.

Rachel Phelan, Hesham Eissa, Kerri Becktell, Neel Bhatt, Matthew Kudek, Brandon Nuechterlein, Lauren Pommert, Ryuma Tanaka, K Scott Baker

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current oncology reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Rachel PhelanChildren's Hospital of Wisconsin/Medical College of Wisconsin, 8701 Watertown Plank Rd, MFRC 3018, Milwaukee, WI, 53122, USA. rphelan@mcw.edu.
Hesham EissaThe University of Colorado, School of Medicine, Blood and Marrow Transplant and Cellular Therapeutics, Center for Cancer and Blood Disorders, Children's Hospital Colorado, 13123 East 16th Avenue, Box B115, Anschutz Medical Campus, Aurora, CO, 80045, USA.
Kerri BecktellChildren's Hospital of Wisconsin/Medical College of Wisconsin, 8701 Watertown Plank Rd, MFRC 3018, Milwaukee, WI, 53122, USA.
Neel BhattSeattle Children's Hospital/University of Washington, 1100 Fairview Ave N, D5-390, Seattle, WA, 98109, USA.
Matthew KudekChildren's Hospital of Wisconsin/Medical College of Wisconsin, 8701 Watertown Plank Rd, MFRC 3018, Milwaukee, WI, 53122, USA.
Brandon NuechterleinThe University of Colorado, School of Medicine, Blood and Marrow Transplant and Cellular Therapeutics, Center for Cancer and Blood Disorders, Children's Hospital Colorado, 13123 East 16th Avenue, Box B115, Anschutz Medical Campus, Aurora, CO, 80045, USA.
Lauren PommertChildren's Hospital of Wisconsin/Medical College of Wisconsin, 8701 Watertown Plank Rd, MFRC 3018, Milwaukee, WI, 53122, USA.
Ryuma TanakaChildren's Hospital of Wisconsin/Medical College of Wisconsin, 8701 Watertown Plank Rd, MFRC 3018, Milwaukee, WI, 53122, USA.
K Scott BakerSeattle Children's Hospital/University of Washington, 1100 Fairview Ave N, D5-390, Seattle, WA, 98109, USA.
Children's Hospital of Wisconsin · USCenter for Cancer and Blood Disorders · USMedical College of Wisconsin · USUniversity of Washington · US

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
Blood and Marrow Transplant Clinical Trials Network DCC- The Medical College of Wisconsin, Inc.U24HL138660 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI Steven M. DeVine, Mehdi Hussain Hamadani · 2017 to 2026
$71.4M
Therapeutic Potential of Adaptive NK Cells in Cancer and TransplantationP01CA111412 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI MILLER, JEFFREY S. · 2005 to 2025
$38.2M
Cure Sickle CellOT3HL147741 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI MARY EAPEN, Mary Maresca Horowitz · 2018 to 2026
$37.7M
Immuno-Oncology Translation Network (IOTN): Cellular Immunotherapy Data Resource (CIDR)U24CA233032 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI PASQUINI, MARCELO C. · 2018 to 2019
$9.0M
Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiencyU01AI126612 · NIAID · CHILDREN'S HOSPITAL OF LOS ANGELES · PI KEAN, LESLIE S, PULSIPHER, MICHAEL A · 2017 to 2023
$8.5M
The role of TCOF1 in germline predisposition to and in leukemic transformation of chronic myelomonocytic leukemiaR01CA152108 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Jing Zhang · 2011 to 2026
$5.4M
Identifying Predictors of Poor Health-Related Quality-of-life among Pediatric Hematopoietic Stem Cell DonorsR01HL131731 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PULSIPHER, MICHAEL A, SWITZER, GALEN E. · 2018 to 2022
$3.6M
Selection of Allogeneic Hematopoietic Cell Donor Based on KIR and HLA GenotypesR01HL129472 · NHLBI · SLOAN-KETTERING INST CAN RESEARCH · PI HSU, KATHARINE C · 2015 to 2019
$2.6M
Hematopoietic Stem Cell Transplantation for Young Adults with SCD - DCCU01HL128568 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI EAPEN, MARY, MENDIZABAL, ADAM M. · 2015 to 2019
$1.7M
Cost Effectiveness Analysis of Stem Cell Transplant in Older MDS PatientsR01HL126589 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI RAMSEY, SCOTT D., SABER, WAEL · 2015 to 2018
$1.7M
Genetics of Graft-versus-Host DiseaseR01CA231141 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI AFSHAR-KHARGHAN, VAHID, GORLOVA, OLGA · 2018 to 2022
$1.6M
NCI NIH HHS P01 CA111412NCI NIH HHS R01 CA152108NCI NIH HHS R01 CA231141NCI NIH HHS U24 CA076518NCI NIH HHS U24 CA233032NHLBI NIH HHS OT3 HL147741NHLBI NIH HHS R01 HL126589NHLBI NIH HHS R01 HL129472NHLBI NIH HHS R01 HL131731NHLBI NIH HHS R21 HL140314NHLBI NIH HHS U01 HL128568NHLBI NIH HHS U24 HL138660NIAID NIH HHS U01 AI126612
6 · The paper itself

Abstract

purpose of reviewAs survival rates of those diagnosed with childhood cancer improve over time, the number of long-term survivors continues to grow. Advances have not only been made in the upfront treatment of childhood cancer, but also in the identification and treatment of late complications that may arise as a result of the chemotherapy, radiotherapy, or surgical interventions required to provide a cure. RECENT

findingsAs new therapies emerge that are often more targeted to cancerous cells while sparing healthy tissues, the hope is that cure can be achieved without the same long-term side effects for survivors. However, much is unknown regarding how these novel interventions will impact patients in the years to come. It is critical that we continue to follow patients treated with new modalities in order to identify and treat the long-term complications that may arise in future childhood cancer survivors.

Indexed as

Cancer SurvivorsCardiovascular DiseasesChildCognition DisordersDisease ProgressionEndocrine System DiseasesHumansNeoplasmsRisk FactorsSurvival RateChildhood cancerLate effectsLong-term complicationsNovel therapySurvivorship

Identifiers

PMID31768799
OpenAlexW2990668555

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.